Oncology

Radnet acquires Gleamer for up to €230M

Tue, 03 Mar 2026 12:00:00 -0500

Radnet Inc. acquired Gleamer SAS for up to €230 million (US$267 million) as it continues to expand its position across imaging and acute diagnostic care, while accelerating its move toward AI-powered automated diagnostics. Gleamer will be integrated into Radnet’s subsidiary, Deephealth Inc., strengthening its imaging portfolio, and positioning the company as the world’s largest provider of radiology clinical AI solutions.

Grail shares plunge after Galleri test misses primary endpoint

Fri, 20 Feb 2026 12:00:00 -0500

Grail Inc.’s share price dropped more than 50% in premarket trading Feb. 20 after it reported late the day before that the NHS-Galleri trial did not meet its primary endpoint. The U.K study, done though the National Health Service with 142,000 individuals enrolled, evaluated the ability of Grail’s Galleri multicancer early detection test to look for cancer-specific methylation patterns in blood.

AI transforming med tech in 2026; clinical need drives investments

Wed, 18 Feb 2026 12:00:00 -0500

Med-tech companies with an AI component in their solutions will certainly find investors willing to back them. AI after all, is being used to develop more effective, smarter technologies. However, investors will only deploy capital into innovations that address genuine clinical needs. The aging population is driving interest in devices targeting cardiovascular and musculoskeletal disorders, and other solutions geared toward neurological conditions, women’s health and diagnostics are also attracting investor attention.

Innovent-Lilly $8.5B deal signals new China inflection point

Tue, 10 Feb 2026 11:00:00 -0500

The scale of the $8.5 billion deal signed between Innovent Biologics Inc. and Eli Lilly and Co. is eye-catching, but the structure is the real signal. By shifting phase II oncology development to China while reserving global rights ex-greater China, the partners are testing a model that could reshape how multinational drugmakers source innovation as well as how Chinese biotechs create value.

Iambic raises the bard in AI, pens $1.7B Takeda deal

Tue, 10 Feb 2026 11:00:00 -0500

Iambic Therapeutics Inc.’s multiyear technology and discovery pact with Takeda Pharmaceutical Co. Ltd. could help the San Diego-based firm advance its own pipeline in a big way.

Iambic raises the bard in AI, pens $1.7B Takeda deal

Mon, 09 Feb 2026 12:00:00 -0500

Iambic Therapeutics Inc.’s multiyear technology and discovery pact with Takeda Pharmaceutical Co. Ltd. could help the San Diego-based firm advance its own pipeline in a big way.

Innovent-Lilly $8.5B deal signals new China inflection point

Mon, 09 Feb 2026 12:00:00 -0500

AI-based tool for breast cancer cuts rate of interval cancers

Mon, 02 Feb 2026 12:00:00 -0500

An AI-based software developed by Screenpoint Medical BV could help detect breast cancers earlier and reduce the number of cancers that appear between routine screenings. In a trial of over 100,000 women, the use of the company’s Transpara Detection system resulted in a 12% reduction in the rate of interval cancers, compared to standard mammography screening. The results from the Mammography Screening with Artificial Intelligence study was published in the Lancet.

Samantree secures €20M from the EIB

Wed, 28 Jan 2026 11:00:00 -0500

Samantree Medical SA is the latest med-tech company to secure financing from the European Investment Bank, highlighting the bank’s commitment to supporting key medical technologies across the continent. The company received a €20 million (US$23.95 million) loan which will go towards accelerating the development and commercialization of its Histolog Scanner, which allows surgeons and pathologists to visualize large, fresh tissue samples in real-time with high resolution and accuracy.

NICE wants more evidence for Barrett’s esophagus treatment

Mon, 26 Jan 2026 11:00:00 -0500

Cryoablation for Barrett’s esophagus is something of a novelty, and the U.K. National Institute of Health and Care Excellence is considering an endorsement of the treatment.

FDA clears 11 Aidoc AI triage indications

Wed, 21 Jan 2026 11:00:00 -0500

Aidoc Medical Ltd.'s Care AI foundation model secured 11 new U.S. FDA-cleared indications for use in emergency department triage. Now, with 14 total cleared indications enabling comprehensive evaluation and prioritization of abdomen CTs in a single workflow, Aidoc Care can help health systems identify critical findings more quickly and mitigate delays caused by overcrowding and imaging backlogs.

F.Med redefines the future of microsurgical robotics

Wed, 21 Jan 2026 11:00:00 -0500

Microsurgery is performed to connect small human vessels, but the technical difficulty required to conduct this type of surgery is quite specialized and limits the number of surgeons who can perform microsurgery.

Rakuten closes $100M series F round, teams with Lotte Biologics

Tue, 20 Jan 2026 11:00:00 -0500

Rakuten Medical Inc. raised $100 million in a series F round to support late-stage clinical development of ASP-1929, its Alluminox-derived photoimmunotherapy being tested with Keytruda (pembrolizumab) as a first-line treatment for recurrent head and neck cancer.

Colostat, Genetype pairing sharpens cancer screening pathway

Fri, 16 Jan 2026 11:00:00 -0500

Rhythm Biosciences Ltd. launched a new genetype colorectal cancer risk assessment clinical test that incorporates clinical and lifestyle risk factors alongside its established 140-SNP polygenic risk score to identify people at elevated risk of colorectal cancer. The test supports more targeted screening and complements Melbourne-based Rhythm’s Colostat blood-based CRC detection test, which debuted in Australia in December 2025.

Cellbxhealth restructures for growth

Mon, 12 Jan 2026 11:00:00 -0500

Cellbxhealth plc, previously called Angle plc, appointed CEO Peter Collins along with several non-executives to its board as it embarks on a new strategic direction. Over the past few months the company overhauled its management team, reduced its workforce by 60% and raised £8.2 million (US$11 million) as it changes focus from research to commercialization of its Parsortix system, a platform that captures and harvests circulating tumor cells (CTCs).

Patent for wearable speech-sensing device filed

greg.kaplan@clarivate.com — Fri, 09 Jan 2026 11:00:00 -0500

Jun Chen, a tenured associate professor of bioengineering at the Samueli School of Engineering at the University of California Los Angeles (UCLA), leads a team developing a speech-sensing wearable patch. The technology translates the intricate muscle movements of the larynx into discernible speech.

China slashes tariffs on some medical devices

Fri, 09 Jan 2026 11:00:00 -0500

Beginning Jan. 1, 2026, China will apply provisional import tariff rates lower than the most-favored-nation rates on 935 items, the State Council announced. The move aims to boost collaboration between domestic and international sectors, and to leverage resources of both to expand the supply of high-quality goods.

Tensive sees positive safety data for bioabsorbable breast implant

Thu, 08 Jan 2026 11:00:00 -0500

Tensive Srl reported positive data from its pivotal trial confirming the safety profile of Regenera, its bioabsorbable breast implant, and its potential to transform breast reconstruction. The pivotal trial, evaluating the Regenera in patients undergoing lumpectomy, found it to be safe, biocompatible and feasible for volume replacement in breast-conserving surgery.

Med techs prune, purchase to rebalance product portfolios

Fri, 02 Jan 2026 11:00:00 -0500

Four optimization trends dominated the med-tech industry in 2025. Growth-driven acquisitions propelled major players into hot markets, while strategic realignments at several large companies prompted notable exits as well as a few tuck-in deals. Spin-offs continued their mixed performance, with several companies on track for significant splits and others changing plans. Private equity entered — and exited — with leveraged buy outs, and a record-setting cash out.

Blossomhill advancing EGFR, CLK inhibitors with series B extension

Wed, 31 Dec 2025 12:00:00 -0500

Wife-and-husband team, J. Jean Cui and Y. Peter Li, launched Blossomhill Therapeutics Inc. in mid-2020 to focus on next-generation, macrocyclic inhibitors against oncology targets. The couple had planned to take some time off to rest and do a little traveling, but then the pandemic hit. “This was a great time [to start a new company],” Cui told BioWorld. “Nothing to do but reading and thinking.”

Bayosthiti AI to build India-specific RNA sequencing ecosystem

Wed, 31 Dec 2025 09:00:00 -0500

Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the Indian market, leveraging intellectual property from its parent company, Biostate AI Inc.

Laparoscopic instruments maker Livsmed tops 2025 Kosdaq IPOs

Mon, 29 Dec 2025 11:00:00 -0500

Livsmed Inc. closed the year’s biggest Kosdaq IPO with a ₩135.85 billion (US$94 million) haul Dec. 24. Livsmed specializes in the development of hand-held multi-joint laparoscopic surgical instruments for minimally invasive procedures.

Big pharma taps fast Asia innovation in search of next Keytruda

Tue, 23 Dec 2025 12:00:00 -0500

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab), Merck & Co. Inc.’s reigning blockbuster cancer drug.

Bayosthiti AI to build India-specific RNA sequencing ecosystem

Tue, 23 Dec 2025 00:00:00 -0500

Natera envisions cancer-testing future with $450M Foresight buy

Fri, 05 Dec 2025 11:00:00 -0500

Natera Inc. completed the acquisition of Foresight Diagnostics Inc. in a deal structured as $275 million up front plus contingent payments of up to $175 million based on achieving certain milestones for revenue and reimbursement coverage. The companies expect to close the transaction in the second quarter of 2026.

Cancer blood test maker Freenome going public with $330M SPAC

holland.johnson@clarivate.com — Fri, 05 Dec 2025 11:00:00 -0500

Freenome Holdings Inc. reported it is going public via a special purpose acquisition company. The company said it expects to raise $330 million, which it plans to use for the 2026 launch of its blood-based screening tests for multiple cancers. Backed by an affiliate of Perceptive Advisors - Perceptive Capital Solutions Corp. (PCSP) – and joined by RA Capital, the arrangement includes a commitment of $240 million in equity investments plus about $90 million more held by the SPAC’s trust fund. Other notable investors, including ADAR1 Capital, Bain Capital Life Sciences, and Farallon Capital Management have signed on to participate in the deal.

Laigo raises €11.5M seed money for targeted protein degradation

Thu, 04 Dec 2025 12:00:00 -0500

Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by E3 ubiquitin ligases.

Antegenes’ risk score offers assurances to people at cancer risk

Mon, 01 Dec 2025 11:00:00 -0500

The recommendation by a committee advising the U.K. government that screening for prostate cancer should not be made available to the vast majority of men could benefit companies such as Antegenes OÜ. The Estonia-based company develops polygenic risk score-based testing kits which help clarify an individual's genetic predisposition to specific cancers, providing a more targeted approach.

Prognomiq launches Provue Lung LDT for early lung cancer ID

holland.johnson@clarivate.com — Wed, 26 Nov 2025 11:00:00 -0500

Prognomiq Inc. reported the launch of its Provue Lung, a novel blood-based laboratory developed test designed to help improve detection of lung cancer at its earliest, most treatable stages.

ARPA-H sees a bright future for autonomous surgery microbots

Tue, 25 Nov 2025 11:00:00 -0500

The Advanced Research Projects Agency for Health (ARPA-H) is taking aim at the shortage of medical services with a program designed to foster development of micro-robots, or microbots, which will autonomously conduct part or all of a variety of surgical procedures.